Treatment of oxaliplatin-induced peripheral neuropathy by intravenous mangafodipir - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Journal of Clinical Investigation Année : 2014

Treatment of oxaliplatin-induced peripheral neuropathy by intravenous mangafodipir

Résumé

The majority of patients receiving the platinum-based chemotherapy drug oxaliplatin develop peripheral neurotoxicity. Because this neurotoxicity involves ROS production, we investigated the efficacy of mangafodipir, a molecule that has antioxidant properties and is approved for use as an MRI contrast enhancer.
Our study suggests that mangafodipir can prevent and/or relieve oxaliplatin-induced neuropathy in cancer patients. Trial registration. Clinicaltrials.gov NCT00727922. Funding. Université Paris Descartes, Ministère de la Recherche et de l'Enseignement Supérieur, and Assistance Publique-Hôpitaux de Paris.

Dates et versions

hal-01704386 , version 1 (08-02-2018)

Identifiants

Citer

Romain Coriat, Jérôme Alexandre, Carole Nicco, Laurent Quinquis, Evelyne Benoit, et al.. Treatment of oxaliplatin-induced peripheral neuropathy by intravenous mangafodipir. Journal of Clinical Investigation, 2014, 124 (1), pp.262 - 272. ⟨10.1172/JCI68730⟩. ⟨hal-01704386⟩
140 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More